{"article_title": "Have We Seen Peak Pharma? Valeant Lowers Drug Prices in Walgreens Deal", "article_keywords": ["lowers", "pharma", "deal", "drugs", "walgreens", "valeant", "drug", "research", "peak", "amid", "prices", "seen", "valeants", "company", "price", "pricing"], "article_url": "http://www.thefiscaltimes.com/2015/12/16/Have-We-Seen-Peak-Pharma-Valeant-Lowers-Drug-Prices-Walgreens-Deal", "article_text": "Amid increased scrutiny of recent drug price hikes from lawmakers and regulators, Valeant Pharmaceuticals announced Tuesday plans to lower prices on some of its prescription drugs this year.\n\nBy the end of 2016, the company will be making some of its branded drugs available to consumers at generic prices, for an average of 50 percent less than the current price. The agreement will cover more than 8,000 Walgreens and independent pharmacies and could amount to more than $600 million in price cuts in total.\n\nThe move comes amid growing public outcry over Valeant\u2019s pricing practices. Online investment research company Citron Research has called Valeant the \u201cpharmaceutical Enron.\u201d The controversy over Valeant\u2019s business model and practices has pushed company share prices down 75 percent.\n\nRelated: America\u2019s 10 Top Selling Medications\n\n\u201cWe have listened to what the marketplace is saying, and we\u2019ve taken positive steps to respond,\u201d J. Michael Pearson, Valeant Chairman and CEO said in a statement.\n\nThe agreement helped quell concerns about how Valent would make up revenue after cutting ties with mail-order pharmacy Philidor Rx Services, amid accusations about the relationship between the two companies.\n\nValeant\u2019s stock price shot up by 10 percent after Tuesday\u2019s news, as investors cheered the \u2018credibility boost\u2019 that came with the news.\n\nPrescription drug pricing has become a hot-button election issue, with Hillary Clinton and Donald Trump both criticizing Turing Pharmaceuticals for raising the price of a long-standing drug used to treat AIDS and cancer patients by 5,000 percent.\n\nIn 2013, Americans spent more than $260 billion, or 9 percent of all health care dollars, on prescription drugs.", "article_metadata": {"og": {"site_name": "The Fiscal Times", "description": "Amid", "title": "Have We Seen Peak Pharma? Valeant Lowers Drug Prices in Walgreens Deal", "url": "http://www.thefiscaltimes.com/2015/12/16/Have-We-Seen-Peak-Pharma-Valeant-Lowers-Drug-Prices-Walgreens-Deal", "image": "http://cdn.thefiscaltimes.com/sites/default/files/04162014_Walgreens.jpg", "type": "article"}, "twitter": {"url": "http://www.thefiscaltimes.com/2015/12/16/Have-We-Seen-Peak-Pharma-Valeant-Lowers-Drug-Prices-Walgreens-Deal", "image": "http://cdn.thefiscaltimes.com/sites/default/files/04162014_Walgreens.jpg", "creator": "@bethbrav", "card": "summary", "title": "The Fiscal Times"}, "viewport": "initial-scale=1, maximum-scale=1", "description": "Amid", "generator": "Drupal 7 (http://drupal.org)"}, "article_summary": "Amid increased scrutiny of recent drug price hikes from lawmakers and regulators, Valeant Pharmaceuticals announced Tuesday plans to lower prices on some of its prescription drugs this year.\nOnline investment research company Citron Research has called Valeant the \u201cpharmaceutical Enron.\u201d The controversy over Valeant\u2019s business model and practices has pushed company share prices down 75 percent.\nThe move comes amid growing public outcry over Valeant\u2019s pricing practices.\nValeant\u2019s stock price shot up by 10 percent after Tuesday\u2019s news, as investors cheered the \u2018credibility boost\u2019 that came with the news.\nPrescription drug pricing has become a hot-button election issue, with Hillary Clinton and Donald Trump both criticizing Turing Pharmaceuticals for raising the price of a long-standing drug used to treat AIDS and cancer patients by 5,000 percent."}